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Abstract 
The challenge of Cefepime resistance in developing countries is substantial and likely to grow. Emergence of 
Cefepime-resistant bacteria has increased and management  of this has become a therapeutic challenge. The 
production of beta lactamases by most bacteria make them to be resistant to beta lactam antibiotics like 
Cefepime which is common nowadays. Forty clinical isolates of Escherichia coli and Proteus mirabilis from 
different clinical sites were analyzed between March and August, 2013 using standard bacteriological methods. 
The aim of this study was the evaluation of the sensitivity of clinical isolates of Escherichia coli and Proteus 
mirabilis to Cefepime. Their sensitivity against Cefepime (30µg) was determined using disk diffusion method. 
The isolates were divided into three groups: sensitive, intermediate and resistance based on their sensitivity 
pattern.  
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The result showed that Escherichia coli had 29.03% sensitivity, 16.13% intermediate and 58.83% resistance 
while Proteus mirabilishad 22.22% sensitivity, 11.11% intermediate and  66.67%  resistance. The overall 
susceptibility pattern of the clinical isolates to Cefepime is 27.50% sensitivity, 15.00% intermediate and 57.57% 
resistance. There was a great Cefepime- resistance among clinical isolates of E. coli and Proteus mirabilis 
analyzed. The resistance pattern of E. coli and Proteus mirabilis calls for continuous surveillance for Cefepime 
resistance control. 
Keywords:Cefepime; LAUTECH; Ogbomoso; Escherichia coli;Proteus mirabilis; Sensitivity 
1. Introduction 
Enterobacteriaceae are a major cause of infections in hospitalized patients [1]. They are large family of bacteria 
that causes both nosocomial and community-acquired infections. This family includes many more familiar 
pathogens, such as Salmonella spp. and Escherichia coli, as well as Citrobacter spp., Enterobacter spp., 
Klebsiella spp., Proteus spp., and others [2]. Among them, the most frequent are Escherichia coli and 
Enterobacter spp [3]. Proteus mirabilis strains account for about 10 % of uncomplicated urinary tract infections 
[4] and  they are about the fifth most common cause of nosocomial urinary tract infections and  sepsis in 
patients [5, 6]. Uro- pathogenic Proteus mirabilis and  Escherichia coli strains may manifest resistance to 
several antimicrobials, including extended spectrum  cephalosporins, fluoroquinolones, and aminoglycosides [ 
7,8, 9] .  Extended-Spectrum β-Lactamase (ESBL) producing strains of Enterobacteriaceae have emerged as a 
major problem in hospitalized as well as community based patients [10]. These organisms are responsible for a 
variety of infections like urinary tract infection (UTI), septicemia, hospital acquired pneumonia, intra-abdominal 
abscess, brain abscess and related infections. ESBLs are primarily produced by the Enterobacteriaceae family, in 
particular Escherichia coli [11] and are a major cause of hospital acquired infections [12]. Proteus is widespread 
in the environment and ranks third as the cause of hospital-acquired infection [13]. Proteus species are major 
cause of diseases acquired outside the hospital, where many of these diseases eventually required hospitalization 
[14].  P. mirabilis   has been implicated in bacteremia [15] , neonatal meningoencephalitis [16] , empyema [17] 
and osteomyelitis [18]. The usefulness of third-generation Cephalosporins may be diminished by the presence of 
inducible β-lactamases in important nosocomial pathogens [19]. Newer generation of cephalosporins such as 
cefepime, however, retain activity against the strains of Gram-negative bacilli that produce plasmid-mediated β-
lactamases compared to ceftazidime [20]. 
2. Material and Methods  
2.1 Bacterial Isolates 
The study includes clinical isolates of Escherichia coli and Proteus mirabilis obtained by screening samples of 
blood (for blood culture), urine, aspirate, wound, throat, sputum, etc. Forty isolates of Escherichia coli and 
Proteus mirabilis were identified from different clinical specimens between March and August, 2013 using 
standard bacteriological methods. 
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Clinical isolates were isolated and obtained from Medical Microbiology and Parasitology Laboratory of the 
Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso,Oyo State, Nigeria. LAUTECH 
Teaching Hospital, Ogbomoso provides a tertiary level patient care, serves as referral hospital in Ogbomoso and 
provides health care facilities to people of different areas. 
The clinical isolates were identified based on their morphological behavior on various differential media. All 
media were prepared according to the manufacturer’s specification and sterilized at 121°C for 15 minutes at 15 
lb pressure. Further identification was then carried out by standard biochemical test (Bergey’s Manual of 
Determinative Bacteriology Ninth Edition)  and  by comparing their characteristics with those of known taxa, as 
described by [21, 22,23]. 
2.2 Susceptibility Test 
The susceptibility test was conducted using the Kirby- Bauer method of Sensitivity determination. Petri – dishes 
of Mueller Hinton agar were prepared according to the manufacturer’s instruction. 0.1ml of Escherichia coli and 
Proteus mirabilis equivalent to 0.5 McFarland standard was seeded into each of the Petri-dishes containing 
Mueller-Hinton agar using sterile swabs. These were allowed to stand for 45 minutes to enable the inoculated 
organisms to pre-diffusion. The antibiotics discs of Cefepime (30µg ;Oxoid, UK) were aseptically placed on the 
surfaces of the sensitivity agar plates. These were incubated for 18 – 24 hours at 37 0 C and the radial zone of 
inhibitions were taken.  
The results were expressed as susceptible, intermediate or resistant according to criteria developed by Clinical 
Laboratory Standard Institute (CLSI), 2007. 
2.3 Statistical Analysis 
Susceptibility rates were analyzed using t- test, at significant level of ƿ≤0.05. All interval estimates are 95% 
confidence intervals. SPSS program for Windows (version 16.0; SPSS, Inc., Chicago, IL) was used. 
3. Results  
Forty clinical isolates of Escherichia coli and Proteus mirabilis were obtained from different clinical sites as 
shown in Table 1. Out of the forty clinical isolates, 31 (77.50%) were Escherichia coli, and 9 (22.50%) were 
Proteus mirabilis. It is clearly shown that E. coli is more associated with urine specimens, while Proteus 
mirabilis are more common in wound specimen because the highest number of clinical isolates of E. coli was 
found in urine specimen while that of Proteus mirabilis was found in wound specimen. 
Escherichia coli had 29.03% sensitivity, 16.13% intermediate and 54.83% resistance while Proteus mirabilis 
had 22.22% sensitivity, 11.11% intermediate and 66.67% resistance as shown in table 2. The grand 
susceptibility pattern of the organisms to cefepime is 27.50% sensitivity, 15.00% intermediate and 57.50% 
resistance. The highest resistance to cefepime was found in Proteus mirabilis (66.67%) than that of Escherichia 
coli (54.83%). The t-test result from Table 4 shows that there was no significant difference in the effect of 
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Cefepime on Escherichia coli (Mean value = 2.26) when compared with its effect on Proteus mirabilis (Mean 
value = 2.44) at α = 0.05. 
4. Discussions  
Antimicrobial resistance surveillance is essential for effective control of infections and management. In the 
study, we investigated 9(22.50%)  Proteus mirabilis and  31(77.50%)  Escherichia coli   isolates from clinical 
samples collected between March and August, 2013. Out of the forty bacterial isolates tested against cefepime, 
17(54.83%) of E. coli and 6 (66.67%) of Proteus mirabilis were resistance to the antibiotic, this resistance to a 
fourth-generation in cephalosporins has increased for both E. coli and   Proteus mirabilis. The susceptibility rate 
for E. coli and Proteus mirabilis in this study is 29.03% and 22.22% respectively. The susceptibility rate of E 
coli from this study 29.03% is higher than that of Kader and Kumar [24] who had 22.8% susceptibility rate. The 
resistance of E coli (54.83%) to cefepime is higher compare to that reported by [25] which in 2005 there was 
1.7% resistance rate and 0.1% in 2002. In addition, resistance of clinical isolates to the critically important 
antibiotic cefepime, a member of fourth generation of cephalosporins, was observed in this study.  
Table 1: Distribution of Escherichia coli and Proteus mirabilis from different Isolation Sites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results showed that the greatest number of Proteus mirabilis isolates from clinical specimen were from wound 
and representing about 61.54% of all clinical samples from wound. Wounds recorded the highest percentage of 
Proteus mirabilis and this confirms the findings of [26] in Ghana and [27] in Nigeria who found that Proteus 
mirabilis is common in wound infections. This seems that Proteus mirabilis is more common or associated with 
Isolation Site Escherichia coli Proteus mirabilis Total (%) 
Wound 5 8 13(32.50) 
Blood 1 0 1(02.50) 
Ear 0 1 1(02.50) 
High Vaginal 2 0 2(05.00) 
Urine 16 0 16(40.00) 
Sputum 0 0 0(00.00) 
Abscess 1 0 1(02.50) 
Catheter 1 0 1(02.50) 
Stool 2 0 2(05.00) 
Eye 2 0 2(05.00) 
Cerebrospinal Fluid 0 0 0(00.00) 
Throat 0 0 0(00.00) 
Aspirate 1 0 1(02.50) 
Total (% ) 31(77.50) 9(22.50) 40(100) 
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wound infections. While the highest isolates for E coli was from urine samples (16 were E coli out 31 isolates) 
compared to other clinical sites.  
With no significant different in the effect of cefepime on the two bacterial species according to the t-test 
disagrees with the report of [28] sthat E. coli is susceptible to quinolones and many other antibiotics; but the 
result agrees with the study by [29], who noted that Proteus is characterized by a statistically limited presence of 
virulence factors but a multi-drug resistance pattern. The resistant of the clinical isolates to cefepime could be as 
a result of abuse of the antibiotics and there should be proper monitoring by qualified personnel in the field to 
curb the trends of antibiotics misuse. 
 
Table 2: Susceptibility of Escherichia coli and Proteus mirabilis to Cefepime using CLSI (2007) Criteria. 
 
Isolation 
site 
Escherichia coli 
 
Proteus mirabilis Grand Total 
S I R Total S I R Total S I R Total  
(% ) 
Wound 1 2 2 5 2 1 5 8 3 3 7 13(32.5) 
Blood 0 0 1 1 0 0 0 0 0 0 1 01(2.5) 
Ear 0 0 0 0 0 0 1 1 0 0 1 01(2.5) 
High 
vaginal 
0 1 1 2 0 0 0 0 0 1 1 02(5) 
Urine 7 1 8 16 0 0 0 0 7 1 8 16(40) 
Sputum 0 0 0 0 0 0 0 0 0 0 0 00(0) 
Abscess 0 0 1 1 0 0 0 0 0 0 1 01(2.5) 
Catheter 0 1 0 1 0 0 0 0 0 1 0 01(2.5) 
Stool 0 0 2 2 0 0 0 0 0 0 2 02(5)  
Eye 1 0 1 2 0 0 0 0 1 0 1 02(5) 
CSF 0 0 0 0 0 0 0 0 0 0 0 00(0) 
Throat 0 0 0 0 0 0 0 0 0 0 0 00(0) 
Aspirate 0 0 1 1 0 0 0 0 0 0 1 01(2.5) 
 
Total (%) 
 
9(29.03) 5 (16.13) 17(54.83) 31(100) 2 22.22) 1(11.11) 6(66.67) 9(100) 11(27.50) 6 (15.00) 23 (57.50) 40 (100) 
 
Key: CLSI, (2007) Susceptibility Criteria for Cefepime; R≤ 14mm or I= 15-17mm or S≥ 18mm 
          S- Sensitive; I- Intermediate; R- Resistance. 
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Table 3: T- test  for the effect of Cefepime on Escherichia coli  and Proteus mirabilis 
Organism Effect Mean value t-value 
Escherichia coli 
 
2.26 0.553 
Proteus mirabilis 2.44 0.557 
                    ƿ≤0.05 
 
5. Study Limitations 
The data collected were limited to Ogbomoso Township in Oyo State of Nigeria; for a period of six months, 
there was a challenge of number of bacterial isolates obtained for that period. 
6. Conclusion 
There was a great resistance of Cefepime to the clinical isolates of Escherichia coli and Proteus mirabilisused in 
the study. 
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